What Is ITPP? Dosage, Half-Life & How to Track It

What ITPP is and how it works

ITPP is a synthetic derivative of inositol, a naturally occurring sugar alcohol, engineered to bind hemoglobin the way 2,3-BPG (a natural molecule inside red blood cells) does — but with a stronger and longer-lasting effect. That binding shifts the oxygen-hemoglobin dissociation curve to the right, meaning hemoglobin holds onto oxygen less tightly and releases more of it to surrounding tissue at a given oxygen tension.

Because that mechanism could theoretically improve oxygen delivery to poorly perfused tissue, ITPP has been studied in several distinct research contexts: oncology (tumors are often hypoxic, and there is a hypothesis that better-oxygenated tumors respond better to radiation and chemotherapy), cardiovascular/ischemia research (limiting damage during reduced blood flow), and informally in endurance-performance circles interested in any compound that touches oxygen delivery.

Worth being very direct about this one: essentially all of the evidence is preclinical, in rodent and cell-culture models, from a limited number of research groups. There is no published human clinical trial data, no established human dosing protocol, no measured human half-life, and no human safety data. It is not approved for any use and is not sold as a peptide vial the way most of this library is — it more closely resembles an experimental research chemical.

Dosing & research status

Because ITPP has not progressed to human trials, there is no dosing protocol to responsibly cite here — animal studies have used a range of subcutaneous and intraperitoneal doses in rodent models, none of which translate directly to a human-equivalent number without the kind of dose-scaling work that has not been published. Any specific milligram figure circulating in research-chemical or performance forums is an extrapolation, not a studied human dose.

This is one of the compounds in this library where the honest answer to "how much do I take" is that the question is premature — the research is still asking whether and how it works in a mammalian system generally, not what a safe or effective human dose looks like.

Half-life & what it means for frequency

There is no published human half-life for ITPP. Rodent pharmacokinetic data exists in some of the published studies but has not been translated into a human-relevant estimate, and species differences in metabolism make that kind of extrapolation unreliable without dedicated human PK studies that have not been done.

Given the complete absence of human data, frequency of dosing in any protocol circulating online should be read as speculative — modeled on animal study schedules, not on anything measured in people.

What to track & common side effects

There is no established human side-effect profile for ITPP. Animal studies have not consistently reported major toxicity at studied doses, but the absence of adverse findings in rodent research is not equivalent to a human safety signal — this compound has essentially no track record in people.

Given how early-stage and thinly documented ITPP is, anyone tracking use of it should prioritize documenting any and every unusual symptom, not just an intended effect — the evidence base here does not support treating side effects as a known, bounded list the way it does for a clinically studied peptide.

Frequently asked questions